BGLC Stock Price, Bionexus Gene Lab Corp. Quote, Chart

Market Summary

USD0.58+0.01

Delayed

1.75%

BGLC Stock Price

View Fullscreen

BGLC RSI Chart

BGLC Valuation

Market Cap

10.2M

Price/Earnings (Trailing)

-3.85

Price/Sales (Trailing)

1.05

EV/EBITDA

-1.74

Price/Free Cashflow

-8.41

BGLC Price/Sales (Trailing)

BGLC Profitability

Operating Margin

13.56%

EBT Margin

-26.99%

Return on Equity

-28.51%

Return on Assets

-23.87%

Free Cashflow Yield

-11.88%

BGLC Fundamentals

BGLC Revenue

Revenue (TTM)

9.8M

Rev. Growth (Yr)

0.2%

Rev. Growth (Qtr)

4.79%

BGLC Earnings

Earnings (TTM)

-2.7M

Earnings Growth (Yr)

-50.23%

Earnings Growth (Qtr)

-133.64%

Breaking Down BGLC Revenue

Last 30 days

-7.9%

Last 90 days

-43.7%

Trailing 12 Months

7.4%

How does BGLC drawdown profile look like?

BGLC Financial Health

Current Ratio

4.61

BGLC Investor Care

Buy Backs (1Y)

89.83%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	9.8M	0	0	0
2023	10.3M	10.4M	10.3M	9.8M
2022	12.9M	12.3M	11.3M	10.9M
2021	11.8M	13.8M	14.2M	13.4M
2020	0	0	0	11.4M
2019	0	0	0	0
2018	0	0	0	212.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Which funds bought or sold BGLC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-18,106	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-7,907	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-3,090	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	3,954	16,718	-%
May 13, 2024	HRT FINANCIAL LP	new	-	15,000	15,000	-%
May 13, 2024	UBS Group AG	new	-	5,943	5,943	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Feb 26, 2024	Virtu Financial LLC	reduced	-56.19	-36,000	14,000	-%

Are Funds Buying or Selling BGLC?

Are funds buying BGLC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BGLC

No. of Funds

Unveiling Bionexus Gene Lab Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 23, 2024	erayak power solution group inc.	18.18%	2e+06	SC 13G
Jan 17, 2024	lai soo kow	025%	1,250,001	SC 13D
Oct 17, 2023	wong chan chong	5.80%	10	SC 13G

Recent SEC filings of Bionexus Gene Lab Corp.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	10-K	Annual Report
Apr 01, 2024	8-K	Current Report
Mar 28, 2024	NT 10-K	NT 10-K
Mar 26, 2024	10-Q/A	Quarterly Report
Feb 29, 2024	DEF 14C	DEF 14C

Peers (Alternatives to Bionexus Gene Lab Corp.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
APD	58.5B	12.2B	14.71%	-4.63%	23.67	4.81	-7.47%	13.44%
DOW	41.7B	43.5B	4.17%	14.11%	32.86	0.96	-18.61%	-57.39%
CE	17.2B	10.7B	1.84%	46.35%	8.64	1.61	7.11%	34.19%
AVTR	17.0B	6.9B	2.50%	19.86%	65.29	2.47	-6.48%	-57.90%
ALB	15.4B	8.4B	14.63%	-37.60%	45.68	1.84	-4.27%	-90.82%
EMN	11.8B	9.1B	4.60%	20.39%	12.77	1.3	-11.38%	33.67%
MID-CAP
CBT	5.7B	3.9B	11.48%	45.92%	12.68	1.45	-8.19%	39.97%
BCPC	5.1B	929.6M	8.37%	26.01%	44	5.44	-1.74%	15.81%
AVNT	4.2B	3.1B	9.33%	16.67%	40.01	1.34	-6.69%	-83.56%
ARCH	2.9B	3.0B	-1.87%	32.89%	9.11	0.99	-20.68%	-74.38%
SMALL-CAP
CCF	1.2B	404.0M	0.11%	32.60%	36.59	3	24.06%	-25.72%
ASIX	667.0M	1.5B	-6.82%	-28.35%	293.44	0.45	-21.27%	-97.94%
CMT	172.0M	336.4M	-1.31%	-0.84%	9.44	0.51	-12.92%	28.47%
AREC	103.7M	16.7M	-3.68%	-14.38%	-8.76	6.19	-57.58%	-718.66%
AMRS	3.7M	-	-80.00%	-99.58%	-0.01	0.01	-	-

Bionexus Gene Lab Corp. News

Latest updates

Bionexus Gene Lab Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.8%	2,381,851	2,273,067	2,553,686	2,566,848	2,377,205	2,839,575	2,575,086	2,485,101	3,028,945	3,245,271	3,575,966	3,092,171	3,449,159	4,125,886	3,091,012	1,103,516	3,070,026	1,547,100	24,173	21,645	28,088
Cost Of Revenue	0.5%	2,016,820	2,006,512	2,199,354	2,227,134	2,008,308	2,500,349	2,275,587	2,221,130	2,672,612	2,752,900	2,866,772	2,624,564	2,866,594	3,742,882	2,568,790	944,226	2,414,719	37,548	16,499	17,020	-18,822
Gross Profit	36.9%	365,031	266,555	354,332	339,714	368,897	339,226	299,499	263,971	356,333	492,371	709,194	467,607	582,565	383,004	522,222	159,290	655,307	34,323	7,674	4,625	9,266
S&GA Expenses	100.0%	-	-16,955	3,082,128	807,077	536,872	487,852	418,824	454,783	368,036	198,069	383,401	378,046	302,851	493,528	294,005	216,993	328,418	212,321	63,097	81,224	-76,489
EBITDA Margin	-1.1%	-0.26	-0.26	-0.28	-0.04	-0.03	-0.02	0.10	0.09	0.09	0.09	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	636.4%	4,661	-869	4,259	3,042	2,445	77.00	2,072	2,319	3,326	3,986	2,150	3,479	3,358	4,551	2,356	7,432	-3,026	-2,752	-804	-570	-921
Income Taxes	79.5%	-20,068	-97,944	76,418	-46,625	15,990	-75,102	10,114	-1,621	14,299	-474,732	75,169	108,280	-	170,141	-492	487	860	-2,087	28,110	1,179	-1,264
Earnings Before Taxes	-133.0%	-83,689	253,571	-2,532,771	-275,241	-53,076	-127,451	-67,287	-140,283	31,365	-	370,491	136,542	-	-	-	-	-	-	-	-	-
EBT Margin	-1.1%	-0.27	-0.27	-0.29	-0.05	-0.04	-0.03	0.09	0.08	0.08	0.08	-	-	-	-	-	-	-	-	-	-	-
Net Income	-133.6%	-103,757	308,463	-2,609,189	-259,251	-69,066	-156,969	-77,401	-138,662	17,066	89,243	295,322	28,262	338,744	-174,163	234,458	-35,841	1,069,644	-92,576	-22,028	-70,398	-61,467
Net Income Margin	-1.3%	-0.27	-0.27	-0.30	-0.05	-0.04	-0.03	-0.01	0.02	0.03	0.06	0.03	0.03	0.03	0.10	-	-	-	-	-	-	-
Free Cashflow	200.5%	114,001	-113,466	-1,033,348	-36,400	-118,399	513,883	305,231	-197,262	-70,030	481,728	315,459	-905,809	114,621	511,166	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.1%	11,161	11,400	11,466	7,899	8,187	8,740	7,798	8,369	9,175	9,574	9,765	9,448	9,899	10,115	1,013	1,060	1,127	1,231	1,344	1,513	1,607
Current Assets	-1.8%	7,905	8,047	8,270	5,227	5,459	6,022	5,409	5,766	6,601	7,150	7,402	7,099	7,563	7,985	720	763	808	883	1,016	1,171	1,250
Cash Equivalents	-1.6%	5,832	5,929	6,147	1,759	1,973	2,119	1,462	1,340	1,844	2,124	1,700	1,483	2,475	2,788	2,190	1,287	1,397	859	977	1,140	597
Inventory	-5.3%	1,077	1,138	1,108	1,166	900	978	1,096	1,512	1,649	1,522	1,488	1,703	1,469	1,176	19.00	21.00	7.00	8.00	12.00	6.00	10.00
Net PPE	-2.6%	1,472	1,512	1,497	1,397	1,482	1,512	1,440	1,533	1,628	1,634	1,647	1,684	1,708	1,786	277	279	288	313	316	330	345
Liabilities	4.3%	1,817	1,742	1,778	1,935	1,630	2,075	1,375	1,547	2,047	2,395	2,713	2,635	3,106	3,453	1,772	91.00	94.00	109	81.00	123	130
Current Liabilities	5.2%	1,717	1,631	1,644	1,876	1,563	2,004	1,335	1,503	1,985	2,329	2,665	2,576	3,035	3,374	38.00	46.00	47.00	52.00	27.00	64.00	66.00
Shareholder's Equity	-3.2%	9,344	9,658	9,688	5,964	6,557	6,665	6,424	6,822	7,128	7,180	7,052	6,813	6,792	6,662	6,682	6,200	6,192	1,122	1,264	1,390	1,478
Retained Earnings	-5.6%	-1,948	-1,844	-1,781	828	1,087	1,156	1,313	1,391	1,529	1,512	1,423	1,128	1,100	761	-507	-447	-381	-333	-240	-218	-
Additional Paid-In Capital	0%	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011	-5,011
Shares Outstanding	0%	17,668	17,668	17,793	173,718	173,718	14,477	173,718	171,218	171,218	171,218	171,218	171,218	171,218	171,218	-	-	-	-	-	-	-
Float	-	-	-	-	66,500	-	48,487	-	-	-	-	-	41,737	-	-	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	86.8%	-34.44	-261	-899	-22.04	-118	477	309	-195	-37.84	483	316	-905	115	932	755	-157	-977	-58.36	-57.41	-52.93	-48.56
Cashflow From Investing	275.2%	24.00	-13.75	-360	-3.06	-5.06	-49.90	18.00	-221	-197	-76.29	-58.58	-59.88	-295	-416	4.00	20.00	1,712	-7.14	4.00	5.00	-14.63
Cashflow From Financing	117.9%	24.00	11.00	5,747	-2.43	-1.78	-2.27	-1.74	112	-	-4.96	-6.08	-8.63	-8.55	2.00	2.00	-2.99	-6.40	-73.47	-98.63	-5.09	-3.61

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BGLC Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
REVENUE	$ 2,381,851	$ 2,377,205
COST OF REVENUE	(2,016,820)	(2,008,308)
GROSS PROFIT	365,031	368,897
OTHER INCOME	201,847	117,344
OPERATING EXPENSES
General and administrative	(645,906)	(536,872)
LOSS FROM OPERATIONS	(79,028)	(50,631)
FINANCE COSTS	(4,661)	(2,445)
LOSS BEFORE TAX	(83,689)	(53,076)
Tax expense	(20,068)	(15,990)
NET LOSS	(103,757)	(69,066)
Other comprehensive income:
Foreign currency translation loss	(209,908)	(39,039)
COMPREHENSIVE LOSS	$ (313,665)	$ (108,105)
Earnings per share - Basic and diluted	$ (0.018)	$ (0.007)
Weighted average shares outstanding and per share amount have been adjusted for the periods shown to reflect the 12-for-1 reverse stock split effected on July 20, 2023, on a retroactive basis as described in Note 10.	17,667,663	14,476,513

BGLC Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and bank balances	$ 2,489,215	$ 2,623,965
Fixed deposits placed with financial institutions	3,342,966	3,305,371
Trade receivables	839,558	799,674
Other receivables, deposits and prepayments	106,304	122,432
Tax Recoverable	50,441	57,588
Inventories	1,076,953	1,137,770
Total current assets	7,905,437	8,046,800
NON-CURRENT ASSETS
Operating lease right of use assets	128,176	141,544
Property, plant and equipment, net	1,471,638	1,511,618
Other investments	1,656,232	1,699,831
Total non-current assets	3,256,046	3,352,993
TOTAL ASSETS	11,161,483	11,399,793
CURRENT LIABILITIES
Trade payables	1,429,162	1,402,180
Other payables and accrued liabilities	214,735	180,912
Current portion of operating lease liabilities	32,508	34,632
Amount owing to directors	40,129	13,199
Total current liabilities	1,716,534	1,630,923
NON-CURRENT LIABILITIES
Non-current portion of operating lease liabilities	88,846	98,763
Deferred tax liabilities	11,916	12,255
Total non-current liabilities	100,762	111,018
TOTAL LIABILITIES	1,817,296	1,741,941
STOCKHOLDERS' EQUITY
As at March 31, 2024, common stock, no par value; 300,000,000 shares authorized and 17,667,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2023, common stock, no par value; 300,000,000 shares authorized and 17,667,663 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding (on a post-reverse stock split basis)*.	17,191,315	17,191,315
Additional paid in capital	(5,011,891)	(5,011,891)
Accumulated deficit	(1,948,035)	(1,844,278)
Other comprehensive losses	(887,202)	(677,294)
TOTAL STOCKHOLDERS' EQUITY	9,344,187	9,657,852
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 11,161,483	$ 11,399,793

About Bionexus Gene Lab Corp.

BioNexus Gene Lab Corp., through its subsidiary, Chemrex Corporation Sdn. Bhd., engages in the wholesale of chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its chemical raw material products used to produce handrails, bench tops, automotive and aero parts, cleanroom panels, and instruments. The company, through its subsidiary, BioNexus Gene Lab Sdn. Bhd, is also involved in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

CEO	Mr. Sook Keng Yeoh
WEBSITE	bionexusgenelab.com
INDUSTRY	Chemicals
EMPLOYEES	27

Bionexus Gene Lab Corp. Frequently Asked Questions

What is the ticker symbol for Bionexus Gene Lab Corp.? What does BGLC stand for in stocks?

BGLC is the stock ticker symbol of Bionexus Gene Lab Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bionexus Gene Lab Corp. (BGLC)?

As of Fri May 17 2024, market cap of Bionexus Gene Lab Corp. is 10.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BGLC stock?

You can check BGLC's fair value in chart for subscribers.

What is the fair value of BGLC stock?

You can check BGLC's fair value in chart for subscribers. The fair value of Bionexus Gene Lab Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bionexus Gene Lab Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BGLC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bionexus Gene Lab Corp. a good stock to buy?

The fair value guage provides a quick view whether BGLC is over valued or under valued. Whether Bionexus Gene Lab Corp. is cheap or expensive depends on the assumptions which impact Bionexus Gene Lab Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BGLC.

What is Bionexus Gene Lab Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BGLC's PE ratio (Price to Earnings) is -3.85 and Price to Sales (PS) ratio is 1.05. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BGLC PE ratio will change depending on the future growth rate expectations of investors.